高度リンパ節転移を伴う進行胃癌に対する周術期 Capecitabine＋Oxaliplatin療法の第II相試験（OGSG1701）

RINDBeRG試験におけるラムシルマブの投与タイミングにおけるサブグループ解析

Effects of an oral elemental nutritional supplement for gastric cancer with adjuvant S-1 therapy（Phase II trial: OGSG1108）

Neoadjuvant docetaxel, oxaliplatin, and S‑1 therapy for patients with large type 3 or type 4 gastric cancer: short‑term outcomes of a multicenter, phase II study (OGSG1902)

A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2‐positive Chemotherapy‐refractory Gastric Cancer (OGSG1203 HERBIS‐5): Final Results

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S‑1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)

Phase I study of neoadjuvant chemoradiotherapy with S‑1 for clinicallyresectable type 4 or large type 3 gastric cancer in elderly patients aged75 years and older (OGSG1303)

Short‑term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)